Clinical Trials Browser

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Melanoma, Neoplasm Metastasis, Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT04444167 2024-04-25

A Study of Anti-PD-1/CTLA-4 Bispecific AK104 Plus Lenvatinib in First-line Advanced Hepatocellular Carcinoma

Phase 1/2 Completed

59 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT03245151 2023-08-30

Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System Tumors

Phase 1/2 Completed

64 enrolled 29 charts

CNSSarcoma

Glioma, Recurrence, Rhabdomyosarcoma, Central Nervous System Neoplasms, Neuroectodermal Tumors, Primitive, Peripheral

NCT02501096 2023-07-20

A Trial of Lenvatinib (E7080) Plus Pembrolizumab in Participants With Selected Solid Tumors

Phase 1/2 Completed

357 enrolled 28 charts 1 FDA

Tumor-Agnostic

Neoplasms

NCT02432274 2023-07-11

Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults With Osteosarcoma

Phase 1/2 Completed

117 enrolled 32 charts

Sarcoma

Neoplasms, Osteosarcoma

NCT01133756 2023-06-22

E7080 in Combination With Carboplatin + Gemcitabine Versus Carboplatin + Gemcitabine Alone as Second Line Therapy in Patients With Platinum-Sensitive Recurrent Ovarian Cancer by CA125

Phase 1/2 Terminated

7 enrolled 6 charts

Gynecologic

Ovarian Neoplasms

NCT05740215 2023-02-22

Efficacy and Safety Study of F520 Combined With Lenvatinib in the Treatment of Patients With Advanced Solid Tumors

Phase 1/2 Unknown

158 enrolled

Other solid neoplasm

Solid Tumors

NCT01433991 2021-06-08

A Study of E7050 in Combination With E7080 in Participants With Advanced Solid Tumors (Dose Escalation) and in Participants With Recurrent Glioblastoma or Unresectable Stage III or Stage IV Melanoma After Prior Systemic Therapy (Expansion Cohort and Phase 2)

Phase 1/2 Terminated

30 enrolled 42 charts

Other solid neoplasm

Advanced Solid Tumors

NCT01136733 2019-02-27

A Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Treatment

Phase 1/2 Completed

173 enrolled 28 charts

Genitourinary

Carcinoma, Renal Cell

NCT00946153 2019-02-01

Study of Lenvatinib (E7080) in Participants With Advanced Hepatocellular Carcinoma (HCC)

Phase 1/2 Completed

66 enrolled 18 charts

Gastrointestinal

Carcinoma, Carcinoma, Hepatocellular

NCT01133977 2016-10-10

E7080 (Lenvatinib) in Combination With Dacarbazine Versus Dacarbazine Alone as First Line Therapy in Patients With Stage IV Melanoma

Phase 1/2 Completed

97 enrolled 8 charts

Dermatologic

Melanoma

Clinical Trials

KEYNOTE-B98

Keynote B59

A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types

MK-3475-06B

A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor

KEYNOTE-365

MK-3475-03A

KEYMAKER-U02

A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors

A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours

KEYMAKER-U02

KEYMAKER-U02

KEYMAKER-U03

A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations

Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer

A Study of Anti-PD-1/CTLA-4 Bispecific AK104 Plus Lenvatinib in First-line Advanced Hepatocellular Carcinoma

Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System Tumors

A Trial of Lenvatinib (E7080) Plus Pembrolizumab in Participants With Selected Solid Tumors

Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults With Osteosarcoma

E7080 in Combination With Carboplatin + Gemcitabine Versus Carboplatin + Gemcitabine Alone as Second Line Therapy in Patients With Platinum-Sensitive Recurrent Ovarian Cancer by CA125

Efficacy and Safety Study of F520 Combined With Lenvatinib in the Treatment of Patients With Advanced Solid Tumors

A Study of E7050 in Combination With E7080 in Participants With Advanced Solid Tumors (Dose Escalation) and in Participants With Recurrent Glioblastoma or Unresectable Stage III or Stage IV Melanoma After Prior Systemic Therapy (Expansion Cohort and Phase 2)

A Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Treatment

Study of Lenvatinib (E7080) in Participants With Advanced Hepatocellular Carcinoma (HCC)

E7080 (Lenvatinib) in Combination With Dacarbazine Versus Dacarbazine Alone as First Line Therapy in Patients With Stage IV Melanoma